This is consistent with the fact that all our IDH-A specimens (and over 86% of the IDH-A patient population) are ATRX mutant while the IDH-O samples (and most IDH-O gliomas) have ATRX intact. This evidence concerns the gene ATRX and central nervous system cancer.